Clinical Trials Logo

Kidney Neoplasms clinical trials

View clinical trials related to Kidney Neoplasms.

Filter by:

NCT ID: NCT00897637 Completed - Clinical trials for Recurrent Wilms Tumor and Other Childhood Kidney Tumors

Gene Expression Profiles to Categorize Wilms Tumors

Start date: February 2004
Phase: N/A
Study type: Observational

This laboratory study is using gene expression profiling to identify different categories of Wilms tumors. Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.

NCT ID: NCT00896454 Completed - Breast Cancer Clinical Trials

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Start date: November 16, 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering corrected serum calcium </= 11.5 mg/dL (2.9 millimoles /L) by day 10.

NCT ID: NCT00888641 Completed - Kidney Neoplasm Clinical Trials

A Pilot Study of Renal Hypothermia During Partial Nephrectomy

Start date: June 2009
Phase: Phase 1
Study type: Interventional

Renal hypothermia may preserve renal function in patients who require partial nephrectomy. In preparation for a definitive randomized controlled trial this pilot study will assess feasibility and variance data to be used for sample size estimation

NCT ID: NCT00873236 Recruiting - Kidney Cancer Clinical Trials

MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer

Start date: April 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Comparing results of MRI scans done after bevacizumab may help doctors predict a patient's response to treatment and help plan the best treatment. It is not yet known whether giving bevacizumab alone is more effective than giving bevacizumab together with interferon alpha-2a in detecting kidney cancer. PURPOSE: This randomized phase II trial is studying MRI scans of blood vessel changes caused by bevacizumab to see how well it works compared with bevacizumab given together with interferon alpha-2a in treating patients with stage III or stage IV kidney cancer.

NCT ID: NCT00873210 Completed - Renal Cancer Clinical Trials

Study In Patients With Kidney Cancer Treated With Sutent

Start date: May 2009
Phase: N/A
Study type: Observational

Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.

NCT ID: NCT00866320 Completed - Kidney Cancer Clinical Trials

Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab

Start date: February 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with metastatic kidney cancer that has not responded to sunitinib or bevacizumab.

NCT ID: NCT00858975 Withdrawn - Renal Tumors Clinical Trials

Study of Cryotherapy for Renal Tumors

Start date: October 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to study the change of tumor size and serum cytokine in the patients who received cryotherapy for the renal tumors.

NCT ID: NCT00854620 Completed - Kidney Cancer Clinical Trials

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

Start date: December 2007
Phase: Phase 2
Study type: Interventional

Determine time-to-progression (TTP) for an escalating dose schedule for subjects with progressive metastatic renal cell carcinoma treated with sorafenib

NCT ID: NCT00853125 Terminated - Kidney Cancer Clinical Trials

Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Start date: February 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Infusing irradiated donor lymphocytes into the patient may help the patient's immune system kill tumor cells. Giving sunitinib together with irradiated donor lymphocytes may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sunitinib together with irradiated donor lymphocytes works in treating patients with metastatic kidney cancer.

NCT ID: NCT00853021 Completed - Kidney Cancer Clinical Trials

Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney

Start date: December 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Biological therapies, such as aldesleukin, may stimulate the immune system in different ways and stop tumor cells from growing. Giving bevacizumab together with aldesleukin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with aldesleukin works in treating patients with metastatic clear cell carcinoma of the kidney.